Adaptive Biotechnologies Corp. (ADPT) recently announced a strategic partnership with NeoGenomics, Inc. (NEO), a company specializing in oncology testing services. This collaboration aims to enhance monitoring options for minimal residual disease (MRD) in patients with specific blood cancers. The financial details of the agreement remain undisclosed.
Through this partnership, Adaptive's cutting-edge, sequencing-based clonoSEQ platform will be integrated into NeoGenomics' comprehensive and tailored assessment services for complex blood cancers, COMPASS and CHART. This integration will facilitate the evaluation of patients' risk profiles, track disease progression in real-time, and offer personalized treatment strategies.
In pre-market trading, Adaptive's stock stands at $6.52, reflecting a 0.94 percent increase, while NeoGenomics' stock has risen by 2.71 percent to $12.78 on the Nasdaq.
